Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial

Dan Astley, Svatopluk Svetlik, Shelby Barnett, Gareth J. Veal

Open source

DOI
10.1080/17576180.2026.2712785
Published
2026-07-24
Container
Bioanalysis
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17576180.2026.2712785,
  title = {Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial},
  author = {Dan Astley and Svatopluk Svetlik and Shelby Barnett and Gareth J. Veal},
  year = {2026},
  journal = {Bioanalysis},
  doi = {10.1080/17576180.2026.2712785},
  url = {https://doi.org/10.1080/17576180.2026.2712785}
}

RIS

TY  - JOUR
TI  - Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial
AU  - Dan Astley
AU  - Svatopluk Svetlik
AU  - Shelby Barnett
AU  - Gareth J. Veal
PY  - 2026
JO  - Bioanalysis
DO  - 10.1080/17576180.2026.2712785
UR  - https://doi.org/10.1080/17576180.2026.2712785
ER  - 

APA

Astley, D., Svetlik, S., Barnett, S., & Veal, G. J. (2026). Development and validation of a LC-MS/MS method for the quantification of the E-type prostanoid receptor 4 antagonist HTL0039732 in human plasma, for a Phase I/IIa clinical trial. Bioanalysis. https://doi.org/10.1080/17576180.2026.2712785

Source records